HNHA is an inhibitor of HDAC.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 142 | |
4 mg | In stock | $ 255 | |
8 mg | In stock | $ 382 | |
20 mg | In stock | $ 785 | |
40 mg | In stock | $ 1240 |
Description | HNHA is an inhibitor of HDAC. |
Targets&IC50 | HDAC:100 nM |
In vitro | Treatment of cells with HNHA could elicite histone hyperacetylation resulting in an up-regulation of cell cycle arrest, p21 transcription, and an inhibition of HT1080 cell invasion. HNHA was able to inhibit in-vitro HDAC enzyme activity as well as proliferation of human fibrosarcoma cells (HT1080). |
In vivo | Several HDAC inhibitors, including MS-27-275 and a hydroxyamide-based HDAC inhibitors such as SAHA have been investigated extensively and shown to inhibit tumor growth in vivo. |
CAS No. | 926908-04-5 |
Chemical Formula | C17H21NO2S |
Molecular Weight | 303.42 |
Solubility | Ethanol: 15mg/mL(49.44mM) DMSO: 15mg/mL(49.44mM) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom